INTRODUCTION {#sec1-1}
============

In the present era, new oncogenic driver mutations are being discovered in nonsmall cell lung carcinoma (NSCLC). Epidermal growth factor receptor (*EGFR*) mutation is the most common with a prevalence of 5%--15% in Caucasians and 30%--60% in Asian population.\[[@ref1][@ref2]\] In India, the reported frequency varies from 22% to 40%.\[[@ref2]\] Identification of *EGFR* mutations has improved the overall survival in patients with advanced lung adenocarcinoma, being sensitive to tyrosine kinase inhibitors (TKIs) that target the intracellular tyrosine kinase domain of *EGFR*.\[[@ref3]\] Majority of these mutations are reported in adenocarcinoma and involve exons 18--21, the most common being exon 19 deletions and exon 21 L858 R missense point mutations.\[[@ref3]\] The molecular studies are increasingly being performed to detect these mutations on cytology samples so as to select the patients who may be benefitted from TKIs.\[[@ref4]\] Cellblocks obtained by fine needle aspiration cytology (FNAC), endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and effusion samples are being used.\[[@ref5]\] The histopathological subtype can predict not only the overall survival but also the mutation status.\[[@ref6][@ref7][@ref8]\] However, there is a scarcity of data on cytomorphological features that could reliably predict the *EGFR* mutation status. Majority of the histopathological studies comprise of surgically resectable early-stage disease (I-IIIA).\[[@ref7][@ref8]\] FNAC and/or effusion cytology remains the primary modality for diagnosis and molecular testing in approximately 70% cases of lung cancer that are unresectable and at an advanced stage (IIIB--IV). Therefore, the aim of the present study was to evaluate the correlation between cytomorphological features and *EGFR* mutation status in advanced stage lung adenocarcinoma. In addition, the association of clinical and radiological characteristics with *EGFR* mutation was also assessed.

MATERIALS AND METHODS {#sec1-2}
=====================

This was a retrospective study, which was approved by the Institutional Ethics Committee. NSCLC-adenocarcinoma cases diagnosed on FNAC (computed tomography \[CT\]/ultrasonography/palpation-guided FNAC and EBUS-TBNA) with known *EGFR* mutation status were retrieved. Lung cancer database was searched for clinical and radiological details including treatment and clinical outcome. Cytological diagnosis was recorded in each case. Cases with low cellularity, inadequate cells for mutation testing, and squamoid differentiation were excluded from the study.

Image-guided FNAC was performed from primary and/or metastatic sites using a 23-gauge needle by a team of interventional radiologists and cytopathologists. Two to three passes were taken for obtaining adequate sample. Palpation-guided FNAC was performed from cervical lymph nodes using a 22-gauge needle by the cytopathologists, whereas EBUS-TBNA was performed by interventional pulmonologists. In each case, 5--6 direct cytology smears were prepared, of which 3--4 were air-dried and stained with May--Grünwald--Giemsa (MGG) and others were fixed in 95% alcohol and stained with hematoxylin and eosin (H and E). The aspirated material was also transferred to a15-ml falcon tube containing 1% of 1 ml ammonium oxalate and later, fixed in 10% neutral buffered formalin, and processed into formalin fixed paraffin embedded cellblocks. H and E-stained cell block sections were assessed for adequacy/tumor cellularity.

*EGFR* mutation testing was performed in the cases with the cell blocks had at least 100 tumor cells. DNA extraction was performed using Qiagen DnAeasy kit. *EGFR* mutation testing was performed by conventional polymerase chain reaction (PCR) followed by Sanger sequencing. PCR was performed for the known *EGFR* mutations involving exons 18, 19, 20, and 21 using forward and reverse primers.

In the present study, based on *EGFR* mutation status, the cases were categorized into two groups - *EGFR* mutation-positive (*EGFR-p*) and *EGFR* mutation-negative (*EGFR-n*). The cytomorphological features were evaluated in each case by two independent cytopathologists, and finally, a consensus diagnosis was made. Cytologically, adenocarcinoma is characterized by various architectural patterns including three-dimensional clusters, sheets, papillae, acinar clusters and "picket-fence though pattern heterogeneity may be present within the same tumor." The cytomorphological features evaluated included (a) predominant tumor aggregation or pattern (monolayered/flat sheets, papillary clusters, acini, solid overlapping clusters and discrete tumor cells) with each pattern quantified from 0 to 1 (0: absent to few; 1: moderate to predominant); (b) tumor stroma including necrosis (0: absent; 1: present), acute/chronic/mixed inflammatory infiltrate (0: absent; 1: present), extracellular mucin (0: absent; 1: present) and multinucleated giant cells (0: absent; 1: present); (c) nuclear features including nuclear atypia (0: mild; 1: moderate; 2: marked); nuclear margins (0: smooth; 1: irregular); chromatin (0: fine; 1: granular; 2: coarse); nucleoli (0: inconspicuous; 1: conspicuous/prominent) and intra-nuclear cytoplasmic inclusions (INCIs) (0: absent; 1: present); (d) intracellular mucin (0: absent; 1: present) and (e) overall tumor grade/differentiation (0: well; 1: moderate; and 2: poor). The presence of signet ring tumor cells was also noted. Histopathological correlation was sought, wherever available.

Clinical variables such as mean age, sex, smoking status, tumor stage, distant metastasis, and clinical outcome based on radiological response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and performance status, and contrast-enhanced CT (CECT) features such as mean size, pulmonary mass, nodules, lymphadenopathy (mediastinal/hilar), and pleural effusion were also analyzed. The correlation of *EGFR* mutation status with clinical and cytomorphological features was assessed using Fisher\'s exact test (*P* ≤ 0.05 was considered statistically significant).

RESULTS {#sec1-3}
=======

A total of 61 cases of lung adenocarcinoma diagnosed on FNAC over a period of 2 years who underwent *EGFR* mutation testing were initially recruited. Of these, 13 cases were excluded due to low cellularity and inadequate samples for *EGFR* mutation testing.\[[@ref6][@ref7]\] Finally, 48 cases with a cytodiagnosis of adenocarcinoma (*n* = 36), NSCLC favor adenocarcinoma (*n* = 4), and metastatic pulmonary adenocarcinoma (*n* = 8) were included in the study, of which19 cases (39.6%) were *EGFR-p* and 29 cases (60.4%) were *EGFR-n*.

[Table 1](#T1){ref-type="table"} summarizes the FNAC details, cytodiagnosis, and mutation status with treatment details. FNAC was done from metastatic sites in six cases including liver (*n* = 2), supraclavicular lymph node (*n* = 2), para-tracheal lymph node (*n* = 1), and mediastinal lymph node (*n* = 1) in *EGFR-p* group, and two cases in *EGFR-n* group including liver (*n* = 1) and para-tracheal lymph node (*n* = 1). Majority of the patients in *EGFR-p* group received TKIs including gefitinib (53%), erlotinib (32%), and afatinib (10.52%), whereas *EGFR-n* cases received pemetrexed- and cisplatin-based chemotherapy (96%) combined with radiotherapy for distant metastases. Immunohistochemistry (IHC) was used for diagnosis (TTF-1, CK7 and/or napsin A positive and p63 and/or CK 5/6 negative) in seven *EGFR-p* (2 NSCLC-favor adenocarcinoma and 5 metastatic adenocarcinoma) and eight *EGFR-n* cases (4 adenocarcinoma, 2 NSCLC-favor adenocarcinoma, and 2 metastatic adenocarcinoma).

###### 

Fine needle aspiration cytology (procedure, site, cytodiagnosis, and immunohistochemistry), epidermal growth factor receptor mutation type, and treatment information in epidermal growth factor receptor-mutation positive and epidermal growth factor receptor-mutation negative cases

![](CJ-15-11-g001)

Correlation of epidermal growth factor receptor mutation status with demographic and clinicoradiological variables {#sec2-1}
------------------------------------------------------------------------------------------------------------------

Clinicoradiological and demographic data are summarized in [Table 2](#T2){ref-type="table"}. The mean age was comparable in both groups, with majority in the age group of 61--80 years (52.6%) in *EGFR-p* and 55.2% between 41 and 60 years in *EGFR-n* group. *EGFR-p* cases were predominantly females and nonsmokers. All *EGFR-p* cases had Stage IV cancer along with metastatic disease, most commonly involving contralateral lung (63.2%), and pleural fluid being least common (10.5%). In *EGFR-n* cases, metastases most frequently occurred in brain and opposite lung (33.3% each) and least in adrenals and liver (22.2% each). Based on the RECIST scoring, *EGFR-p* status was associated with an overall good clinical outcome in 84.2% cases including partial response (PR) in five cases and stable disease (SD) in 11 cases. Progressive disease (PD) was seen in only 3 (15.8%) cases with a mean follow-up of 6.9 months (2--18 months). However, in *EGFR-n* group, 50% showed poor outcome (PD in 4; poor performance in 6; and death in 3 cases), while 50% showed good response (SD in 6 and PR in 7 cases) with a mean follow-up of 10 months (1 month--2 years).

###### 

Clinicoradiological parameters of epidermal growth factor receptor-mutation positive from epidermal growth factor receptor-mutation negative lung adenocarcinoma

![](CJ-15-11-g002)

On CECT, *EGFR-p* tumors had an overall smaller mean size, majority being \<5 cm. However, no significant difference was observed when radiological parameters such as mass, nodules, lymphadenopathy, or pleural effusion were compared between the two groups.

Correlation of epidermal growth factor receptor mutation status with cytomorphological features {#sec2-2}
-----------------------------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} summarizes the cytomorphological features of *EGFR-p* and *EGFR-n* groups. In each case, tumor patterns/aggregation were quantified from 0 to 1 \[Figures [1](#F1){ref-type="fig"} and [2a](#F2){ref-type="fig"}--[d](#F2){ref-type="fig"}\] and the predominant pattern was noted. There was preponderance of monolayered flat sheets (52.6%) and acini (42%) in *EGFR-p* group (*P* \< 0.01, 0.041, respectively), whereas overlapping solid clusters predominated in *EGFR-n* group (75.9%, *P* = 0.01). Though papillary clusters were more frequent in *EGFR-p* group and discrete tumor cell pattern was more common in *EGFR-n* group, these were not statistically significant. Stromal features such as necrosis (44.8%), acute/chronic/mixed inflammatory infiltrate (58.6%), and giant cells (20.7%) were higher in *EGFR-n* group \[Figure [3a](#F3){ref-type="fig"}, [b](#F3){ref-type="fig"} and [d](#F3){ref-type="fig"}\]. There was no significant difference for extracellular mucin between the two groups, though it was slightly higher in *EGFR-p* group \[21% vs. 13.8%, [Figure 3c](#F3){ref-type="fig"}\]. For the nuclear features \[Figure [4a](#F4){ref-type="fig"}-[d](#F4){ref-type="fig"}\], *EGFR-p* cases revealed a significant association with low nuclear grade in the form of mild nuclear atypia (52.6%), smooth nuclear margins (68.4%), and fine chromatin (57.9%), whereas *EGFR-n* cases had moderate to marked nuclear atypia (44.8% and 55.2%), irregular nuclear margins (93%), and coarse chromatin (65.5%). INCIs were noted in almost similar percentage in the two groups \[[Figure 4](#F4){ref-type="fig"}\]. Intracellular mucin and inconspicuous nucleoli were also found to be higher in *EGFR-p* group than *EGFR-n* group; however, these were not statistically significant. A highly significant difference was noted when overall tumor grade was compared (*P* \< 0.01). *EGFR-p* tumors were predominantly well-differentiated (52.63%) as compared to *EGFR-n* tumors, which were moderate and poorly-differentiated (44.8% and 55.2%, respectively). Two *EGFR-n* cases showed few signet ring tumor cells.

###### 

Cytomorphological features of epidermal growth factor receptor-mutation positive and epidermal growth factor receptor-mutation negative lung adenocarcinoma

![](CJ-15-11-g003)

![Tumor pattern: Epidermal growth factor receptor mutation positive cases showing flat monolayered sheets (a), acini (b), and papillary fragment of tumor cells (c) (H and E, ×400); (d) A solid overlapping cluster in epidermal growth factor receptor mutation negative case (MGG, ×400)](CJ-15-11-g004){#F1}

![Cellblock sections: epidermal growth factor receptor mutation positive cases tall columnar tumor cells with intervening stroma (a), glandular pattern (b), and papillary fragments (c); (d) a solid sheet-like pattern in epidermal growth factor receptor mutation negative case (H and E, ×400)](CJ-15-11-g005){#F2}

![Stromal features: (a) Necrosis in epidermal growth factor receptor mutation negative case; (b) giant cells in epidermal growth factor receptor mutation negative case; (c) abundant extracellular mucin in epidermal growth factor receptor mutation positive case; (d) foamy macrophages (arrows) interspersed with tumor cells in epidermal growth factor receptor mutation positive case (MGG, ×400)](CJ-15-11-g006){#F3}

![Nuclear features: (a) Epidermal growth factor receptor mutation-positive tumor exhibiting mild nuclear atypia with relatively monomorphic nuclei (H and E, ×400); (b) epidermal growth factor receptor mutation-positive tumor with regular and smooth nuclear margins with fine chromatin (MGG, ×400); (c) epidermal growth factor receptor mutation negative tumor showing moderate nuclear atypia (H and E, ×400); (d) epidermal growth factor receptor mutation negative tumor with tumor cells showing irregular nuclear margins and coarse chromatin (MGG, ×400). Intra-nuclear cytoplasmic inclusions identified in both the groups (MGG, ×400; (3b and 4d-inset))](CJ-15-11-g007){#F4}

DISCUSSION {#sec1-4}
==========

There is a limited data describing the cytomorphological features that could suggest mutation status in lung adenocarcinoma, though histopathological subtype is an independent predictor of mutation status.\[[@ref3][@ref6][@ref7]\] *EGFR* mutations have been linked to lung adenocarcinoma with lepidic pattern.\[[@ref9][@ref10]\] With the advent of molecular techniques and targeted therapies, cytology has become an indispensable tool in guiding the diagnosis and management of mutation-positive advanced stage adenocarcinoma.\[[@ref5][@ref11]\] International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society proposed a new classification of lung adenocarcinoma in 2011 that strongly recommended the strategic use of cytology/small biopsy specimens for diagnosis and molecular testing in cases presenting with locally advanced or metastatic disease.\[[@ref12]\] It recommended more specific categorization of NSCLC on cytology/small biopsies into adenocarcinoma or squamous cell carcinoma. The therapeutic implication of this categorization lies in the fact that the patients with *EGFR-p* adenocarcinoma are the potential candidates for TKIs and for pemetrexed and bevacizumab-based chemotherapy if *EGFR-n*.\[[@ref12]\] Thus, *EGFR* mutation, an independent predictor of response to TKIs and survival, should be tested in cytologically diagnosed adenocarcinoma, NSCLC-favor adenocarcinoma or NSCLC-NOS.\[[@ref12]\] FNAC is a minimally invasive, relatively safe, cost-effective and rapid test as compared to lung biopsy and is highly recommended with the intent of early diagnosis and molecular analysis. Cell blocks prepared from aspirated material may have more tumor cells than a small biopsy. In a study by Rekhtman *et al*., 98% (126/128) of the cell block specimens were found to be adequate for *EGFR* (25%) and *KRAS* (20%) mutation testing.\[[@ref13]\] Ma *et al*. performed *EGFR* mutation testing by PCR followed by direct sequencing on cell blocks that were subjected to the enrichment of tumor cells to \>30% by microdissection or at least 50 tumor cells and on surgical specimens. They reported a positive *EGFR* mutation detection rate of 39.4% as compared to 48% in surgical specimens.\[[@ref14]\]

It is important to have good cell blocks with at least 50 tumour cells to extract good quantity and quality DNA material for molecular studies. Previous publications have highlighted various methods to concentrate diagnostic material.\[[@ref15]\] In the absence of cell blocks, air-dried MGG stained cytosmears can also be scraped for DNA extraction.

In lung adenocarcinoma, the independent clinical prognostic factors determining the disease progression or recurrence include age, sex, stage, performance status and smoking.\[[@ref12]\] The predictive factors determining the response to specific therapies include histological subtypes and *EGFR* mutations, each predicting a good response to TKIs and progression-free survival.\[[@ref12]\]

Various studies have reported the association of *EGFR* mutated lung adenocarcinoma with female sex, nonsmoking status and Asian ethnicity.\[[@ref16]\] The present study also corroborates with these findings with preponderance of nonsmokers and females in *EGFR-p* group. The most common mutations reported are exon 19 in-frame deletions and exon 21 L858R missense mutations. In the present study, exon 19 deletions were most frequent (63%) with a ratio of exon 19 to exon 21 mutations being 2:1, in line with the previous studies (1.3:1--4.6:1).\[[@ref17]\] Exon 20 mutations are usually resistant to TKIs, though rarely, better clinical responses have been reported.\[[@ref18]\] We also found one case with exon 20 insertion (9 bp) who received Gefitinib and had SD. Brachtel *et al*. reported 77% of *EGFR* mutated cases to be alive with no evidence of disease at last follow-up as compared to 59% of *EGFR* non-mutated cases.\[[@ref19]\] An Indian study by Maturu *et al*. reported higher median overall survival in cases with *EGFR* mutated type than *EGFR* wild-type and *EGFR* unknown type.\[[@ref20]\] In the present study, *EGFR-p* status was associated with overall good clinical outcome than *EGFR-n* group.

Several studies have shown that lepidic, papillary, micropapillary and acinar subtypes correlate positively and solid subtype has a negative correlation with EFGR mutation, though most of these studies included the resected specimens of stage I-IIIA patients.\[[@ref3][@ref6][@ref7]\] Maturu *et al*. reported a positive association of *EGFR* mutation status with lepidic predominant adenocarcinoma (36.4%) and negative association with solid predominant subtype.\[[@ref20]\] However, only a handful of studies have attempted to correlate the cytomorphological features with *EGFR* mutation in the literature. A cytological study by Brachtel *et al*. comprising of 37 cases of lung adenocarcinoma reported 13 *EGFR-p* (35%) and 24 *EGFR-n* (65%) cases (similar to our study, 39.6% and 60.4%, respectively), wherein the combination of flat architecture, presence of intra-nuclear inclusions, absence of macronucleoli and absence of extracellular mucin correlated significantly with the presence of *EGFR* mutation with a positive predictive value of 69% and a negative predictive value of 92%.\[[@ref19]\] Though presence of overlapping clusters, irregular nuclear membranes and degree of nuclear pleomorphism was higher in the control group, while nuclear grooves and fine chromatin were more common in mutation positive group, these features did not reach a statistical significance. None of the mutation positive cases had extracellular mucin (in contrast to our study).\[[@ref19]\] Marotti *et al*.\[[@ref21]\] in a retrospective analysis of 50 cases of lung adenocarcinoma found 12% cases with *EGFR* mutations and showed a significant correlation of INCIs, papillary fragments, and lepidic predominant adenocarcinoma histology with *EGFR* mutation status (similar to our study).

The present study also supports presence of flat monolayered sheets, acini, less stromal desmoplastic response, mild nuclear atypia, smooth nuclear margins, fine nuclear chromatin, and well-differentiated grade being significantly associated with *EGFR-p* status, whereas *EGFR-n* status is strongly associated with solid overlapping clusters, high desmoplastic stromal response, moderate to marked nuclear atypia, irregular nuclear margins, coarse chromatin, and moderate-to-poor differentiation. In contrast to previous studies, INCIs were not found to have positive correlation with *EGFR-p* tumors.

CONCLUSION {#sec1-5}
==========

The present study supports the indispensable role of cytology as a minimally invasive diagnostic test in lung adenocarcinoma. As documentation of *EGFR* mutation is a prerequisite for initiating TKI therapy in such patients, molecular analysis could be performed on cytological cell blocks. Certain cytomorphological features in an appropriate clinical context may suggest *EGFR* mutation, thereby acting as potential surrogate markers in predicting mutation status.
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